SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...
(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...
With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...
Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program ...
The proportion of patients who have been diagnosed with cancer at an early stage in England is at its highest ever level ...
Her prognosis wasn’t good—about one in three people with the diagnosis she had die within five years—and she would have to ...
A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...
Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...
Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...
Richard Hays, a renowned New Testament scholar and former dean of Duke Divinity School known for his influential books on ...
Tumor Treating Fields therapy demonstrates increased overall survival in patients with unresectable pancreatic cancer. The ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback